Companies Dominating the Hypersensitivity Pneumonitis Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Svizera Healthcare Pvt. Ltd.
- Sanofi S.A.
- Novo Nordisk A/S
- Eli lilly and Company
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Abbott Laboratories Inc.
- Astra Zeneca Plc.
Browse Key Market Insights with Data Illustration:
In the News
- Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer which is the second most common type of cancer in the world.
- Sanofi S.A. an innovative global healthcare company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab) a monoclonal antibody used to treat allergic conditions such as, asthma. Further, is the first and only biologic drug authorized for the treatment of moderate-to-severe atopic dermatitis, and the children treated with Dupixent with topical corticosteroids (TCS) reported that they had cleaner skin and considerably less itching.
